HRT Financial’s Emergent Biosolutions EBS Stock Holding History

HRT Financial’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$464K	Sell	55,443 -220,490	-80%	-$1.84M	﹤0.01%	2747
2026 Q1	$2.29M	Sell	275,933 -35,851	-11%	-$371K	0.01%	1530
2025 Q4	$3.85M	Buy	+311,784	New	+$3.34M	0.01%	906
2025 Q2	–	Sell	-275,716	Closed	-$1.34M	–	2837
2025 Q1	$1.34M	Buy	+275,716	New	+$2.28M	0.01%	991
2024 Q3	–	Sell	-125,357	Closed	-$854K	–	2593
2024 Q2	$854K	Buy	+125,357	New	+$539K	﹤0.01%	1082
2023 Q4	–	Sell	-250,946	Closed	-$853K	–	2482
2023 Q3	$853K	Buy	+250,946	New	+$1.39M	0.01%	1097
2022 Q4	–	Sell	-32,142	Closed	-$674K	–	2616
2022 Q3	$674K	Buy	+32,142	New	+$894K	0.01%	1259
2022 Q2	–	Sell	-5,108	Closed	-$209K	–	3101
2022 Q1	$209K	Buy	+5,108	New	+$225K	﹤0.01%	2466
2019 Q2	–	Sell	-4,073	Closed	-$205K	–	788
2019 Q1	$205K	Buy	+4,073	New	+$240K	0.03%	389

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

HRT Financial's EBS Position: Q2 2026 in Review

HRT Financial reduced its Emergent Biosolutions (EBS) stake by 80% in Q2 2026, selling an estimated $1.84M and leaving 55,443 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #2747.

HRT Financial first reported a position in EBS in Q1 2019 and has held it in 9 quarters since. The position peaked at $3.85M in Q4 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

HRT Financial held 55,443 shares of Emergent Biosolutions worth $464K as of Q2 2026.
HRT Financial sold 220,490 Emergent Biosolutions shares in Q2 2026, an estimated $1.84M.
Emergent Biosolutions made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #2747 holding.
HRT Financial first reported a position in Emergent Biosolutions in Q1 2019 and has held it in 9 quarters since.
HRT Financial's Emergent Biosolutions position peaked at $3.85M in Q4 2025.
194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.